PL EN


Preferences help
enabled [disable] Abstract
Number of results
2016 | 52 | 162-180
Article title

Current status of Helicobacter pylori associated human gastric cancer and the therapeutic approaches – A Review

Authors
Content
Title variants
Languages of publication
EN
Abstracts
EN
In the recent years one of the common causes of cancer related deaths in humans is associated with the development of gastric carcinoma leading to gastric cancer. It had long before reported that the potent agent that is intimately related with the gastric cancer is the infection of the bacterium Helicobacter pylori (H. pylori). H. pylori infection in humans is characterised by the development of acute peptic ulcers which creates a lots of gastroenterological symptoms. Co-existence of H. pylori in the human gastric environment is well adapted by the pathogen by evading the immune responses of the host. Gastric biopsy in patients suffering from H. pylori infection reported the development of gastric lesions having the chance to proceed towards development gastric cancer. Recently it was reported that eradication of the H. pylori colonization is not possible even after continued current antibiotic treatment over long periods and even combined regimes are unsuccessful.Moreover alterations of the genetic background of the host gastric cells were also reported along with infection of H. pylori, the primary concern for the evolution of the genetically transformed cells which is the hallmark for the development of malignancy. Clinical studies have reported the limited efficacy in decreasing the incidence of gastric carcinoma even after the eradication therapy has been completed for the bacterial colonization. Research based on the biopsy specimens obtained from conventional gastric endoscopy of affected patients has revealed some genetic or epigenetic alterations in the gastric mucosa. The cause of concern to human life lies in the fact that the number of sporadic cases of primary or metachronous gastric carcinoma has increased after successful eradication.The purpose of the present review is to assess the current status of the research based on the concept of development of gastric carcinoma in association with H. pylori infection in humans and to throw some light in the remedial measures against the pathogen which is a chronic burden in the well-being of the human society.
Discipline
Year
Volume
52
Pages
162-180
Physical description
References
  • [1] de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M (2012). Global burden of cancers attributable to infections in2008: a review and synthetic analysis, Lancet Oncol, 13: 607-615.
  • [2] Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ (2001). Helicobacterpylori infection and the development of gastric cancer, N Engl J Med, 345: 784-789.
  • [3] de Martel C, Forman D, Plummer M (2013). Gastric cancer: epidemiology and risk factors, GastroenterolClin North Am, 42: 219-240.
  • [4] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2012). Biological agents.Volume100 B.A review of humancarcinogens. IARC Monogr Eval Carcinog Risks Hum, 100: 1-441.
  • [5] Peek RM, Jr., Blaser MJ (2002). Helicobacter pylori and gastrointestinal tract adenocarcinomas, Nat Rev Cancer, 2: 28-37
  • [6] Fox JG, Wang TC (2007). Inflammation, atrophy, and gastric cancer, J Clin Invest 117: 60-69.
  • [7] Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA (2013). Inflammation induced cancer: crosstalk between tumours, immune cells and microorganisms, Nat Rev Cancer13: 759-771.
  • [8] Sepulveda AR (2013). Helicobacter, Inflammation, and Gastric Cancer, Curr Pathobiol Rep, 1: 9-18
  • [9] Sibony M, Jones NL (2012). Recent advances in Helicobacter pylori pathogenesis. Curr Opin Gastroenterol, 28: 30-35.
  • [10] Mégraud F (2004). H pylori antibiotic resistance: prevalence, importance and advances in testing, Gut, 53: 1374-1384.
  • [11] Amieva MR, El-Omar EM (2008). Host-bacterial interactions in Helicobacter pylori infection, Gastroenterology, 134: 306-323
  • [12] Wen S, Moss SF (2009). Helicobacter pylori virulence factors in gastric carcinogenesis. Cancer Lett, 282: 1-8.
  • [13] Higashi H, Nakaya A, Tsutsumi R, Yokoyama K, Fujii Y, Ishikawa S, Higuchi M, Takahashi A, Kurashima Y, Teishikata Y, Tanaka S, Azuma T, Hatakeyama M (2004).Helicobacter pylori CagA induces Ras independent morphogenetic response through SHP-2 recruitment and activation, J Biol Chem, 279: 17205-17216.
  • [14] Backert S, Tegtmeyer N, Selbach M (2010). The versatility of Helicobacter pylori CagA effector protein functions: The master key hypothesis, Helicobacter, 15: 163-176.
  • [15] Uno K, Kato K, Atsumi T, Suzuki T, Yoshitake J, Morita H, OharaS, Kotake Y, Shimosegawa T, Yoshimura T (2007). Toll-like receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells, Am J Physiol Gastrointest Liver Physiol, 293: 1004-1012.
  • [16] Uno K, Kato K, Shimosegawa T (2014). Novel role of toll-like receptors in Helicobacterpylori - induced gastric malignancy. World J Gastroenterol, 20: 5244-5251.
  • [17] Kim KK, Kim HB (2009). Protein interaction network related to Helicobacter pylori infection response. World J Gastroenterol, 15: 4518-4528.
  • [18] ChattopadhyayS, Patra R, Chatterjee R, De R, Alam J, Ramamurthy T, Chowdhury A, Nair GB, Berg DE, Mukhopadhyay AK (2012). Distinct repeat motifs at the C-terminal region of CagA of Helicobacter pylori strains isolated from diseased patients and asymptomatic individuals in West Bengal, India, Gut Pathog, 4: 4.
  • [19] Smoot DT, Elliott TB, Verspaget HW, Jones D, Allen CR, Vernon KG, Bremner T, Kidd LC, Kim KS, Groupman JD, Ashktorab H (2000). Influence of Helicobacter pylori on reactive oxygen-induced gastric epithelial cell injury, Carcinogenesis, 21: 2091-2095.
  • [20] Nahar S, Mukhopadhyay AK, Khan R, Ahmad MM, Datta S,Chattopadhyay S, Dhar SC, Sarker SA, Engstrand L, Berg DE, Nair GB, Rahman M (2004). Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh, J Clin Microbiol, 42: 4856-4858.
  • [21] Eaton KA, Morgan DR, Krakowka S (1989). Campylobacter pylori virulence factors in gnotobiotic piglets, Infect Immun, 57: 1119-1125.
  • [22] Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R, Covacci A (1996). Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA, 93: 14648-14653.
  • [23] Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis GF, Trust TJ (1999). Genomic sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori, Nature, 397: 176-180.
  • [24] Simán JH, Forsgren A, Berglund G, Florén CH (2001). Tobacco smoking increases the risk for gastric adenocarcinoma among Helicobacter pylori-infected individuals. Scand J Gastroenterol, 36: 208-213.
  • [25] Tegtmeyer N, Wessler S, Backert S (2011). Role of the cag-pathogenicity island encoded type IV secretion system in Helicobacter pyloripathogenesis, FEBS J, 278: 1190-1202.
  • [26] Murata-Kamiya N, Kikuchi K, Hayashi T, Higashi H, Hatakeyama M (2010). Helicobacter pylori exploits host membrane phosphatidylserine for delivery, localization, and pathophysiological action of the CagA oncoprotein, Cell Host Microbe, 7: 399-411
  • [27] Fischer W (2011). Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus, FEBS J, 278: 1203-1212.
  • [28] Gopal GJ, Pal J, Kumar A, Mukhopadhyay G (2015). C-terminal domain of CagX is responsible for its interaction with CagT protein of Helicobacter pylori type IV secretion system, Biochem Biophys Res Commun, 456: 98-103.
  • [29] Amieva MR, El-Omar EM (2008). Host-bacterial interactions in Helicobacter pylori infection, Gastroenterology, 134: 306-323
  • [30] Fischer W, Prassl S, Haas R (2009). Virulence mechanisms and persistence strategies of the human gastric pathogen Helicobacter pylori, Curr Top Microbiol Immunol, 337: 129-171
  • [31] Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, AburataniH, Akiyama T, Peek RM, Azuma T, Hatakeyama M (2007). Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal trans-differentiation in gastric epithelial cells, Oncogene, 26: 4617-4626.
  • [32] Saadat I, Higashi H, Obuse C, Umeda M, Murata-Kamiya N, Saito Y, Lu H, Ohnishi N, Azuma T, Suzuki A, Ohno S, Hatakeyama M (2007). Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature, 447: 330-333.
  • [33] Marcus EA, Vagin O, Tokhtaeva E, Sachs G, Scott DR (2013). Helicobacter pylori impedes acid-induced tightening of gastric epithelial junctions. Am J Physiol Gastrointest Liver Physiol, 305: G731-G739.
  • [34]Lu H, Murata-Kamiya N, Saito Y, Hatakeyama M (2009). Role of partitioning-defective 1/microtubule affinity-regulating kinases in the morphogenetic activity of Helicobacter pylori CagA, J Biol Chem, 284: 23024-23036
  • [35] Osman MA, Bloom GS, Tagoe EA (2013). Helicobacter pylori induced alteration of epithelial cell signaling and polarity: a possible mechanism of gastric carcinoma etiology and disparity, Cytoskeleton, 70: 349-359.
  • [36] Klein PD, Graham DY, Gaillour A, Opekun AR, Smith EO (1991). Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group, Lancet, 337: 1503-1506.
  • [37] Loh JT, Shaffer CL, Piazuelo MB, Bravo LE, McClain MS, Correa P,Cover TL(2011). Analysis of cagA in Helicobacter pylori strains from Colombian populations with contrasting gastric cancer risk reveals a biomarker for disease severity, Cancer Epidemiol Biomarkers Prev, 20: 2237-2249.
  • [38] Ferreira RM, Pinto-Ribeiro I, Wen X, Marcos-Pinto R, Dinis-Ribeiro M, Carneiro F, Figueiredo C (2015). Helicobacter pylori cagA promoter region sequences influence CagA expression and interleukin8 secretion, J Infect Dis.
  • [39] Cover TL, Blanke SR(2005). Helicobacter pylori VacA, a paradigm for toxin multifunctionality, Nat Rev Microbiol, 3: 320-332
  • [40] Boquet P, Ricci V (2012). Intoxication strategy of Helicobacter pylori VacA toxin, Trends Microbiol, 20: 165-174.
  • [41] Kim IJ, Blanke SR (2012). Remodeling the host environment: modulationof the gastric epithelium by the Helicobacter pylori vacuolating toxin (VacA), Front Cell Infect Microbiol 2: 37.
  • [42] Cover TL, Blaser MJ (1992). Purification and characterization of the vacuolating toxin from Helicobacter pylori, J BiolChem 267: 10570-10575.
  • [43] Gangwer KA, Mushrush DJ, Stauff DL, Spiller B, McClain MS, Cover TL, Lacy DB, (2007). Crystal structure of the Helicobacter pylori vacuolatingtoxin p55 domain, Proc Natl Acad Sci USA 104: 16293-16298.
  • [44] Forsyth MH, Atherton JC, Blaser MJ, Cover TL (1998). Heterogeneity in levels of vacuolating cytotoxin gene (vacA) transcription among Helicobacter pylori strains, Infect Immun, 66: 3088-3094.
  • [45] Ilver D, Arnqvist A, Ogren J, Frick IM, Kersulyte D, Incecik ET, Berg DE, Covacci A, Engstrand L, Borén T (1998). Helicobacter pylori adhesion binding fucosylated histo-blood group antigens revealed by retagging, Science 279: 373-377.
  • [46] Mahdavi J, Sonden B, Hurtig M,Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S, WadstromT, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarstrom L, Boren T (2002). Helicobacter pylori SabAadhesin in persistent infection and chronic inflammation, Science, 297: 573-578.
  • [47] Aspholm M, Olfat FO, Nordén J, Sondén B, Lundberg C, Sjöström R, Altraja S, Odenbreit S, Haas R, Wadström T, Engstrand L, Semino-Mora C, Liu H, Dubois A, Teneberg S, Arnqvist A, Borén T(2006).SabA is the H. pylori hemagglutinin and is polymorphic in binding tosialylatedglycans, PLoSPathog, 2: e110.
  • [48] Scott D, Weeks D, Melchers K, Sachs G (1998). The life and death of Helicobacter pylori, Gut, 43 Suppl 1: S56-S60
  • [49] Kuipers EJ, Uyterlinde AM, Peña AS, Roosendaal R, Pals G, Nelis GF, Festen HP, Meuwissen SG (1995). Long-term sequelae of Helicobacter pylori gastritis, Lancet, 345: 1525-1528
  • [50] Sipponen P, Kekki M, Haapakoski J, Ihamäki T, Siurala M (1985). Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data, Int J Cancer, 35: 173-177
  • [51]Honda S, Fujioka T, Tokieda M, Satoh R, Nishizono A, Nasu M (1998). Development of Helicobacter pylori-induced gastric carcinoma in Mongolian gerbils, Cancer Res, 58: 4255-4259
  • [52]Rieder G, Merchant JL, Haas R (2005). Helicobacter pylori cag-type IV secretion system facilitates corpus colonization to induce precancerous conditions in Mongolian gerbils, Gastroenterology, 128: 1229-1242
  • [53]Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M (1998). Helicobacter pylori infection induces gastric cancer in mongolian gerbils, Gastroenterology, 115: 642-648
  • [54] Blaser MJ, Atherton JC (2004). Helicobacter pylori persistence: biologyand disease. J Clin Invest, 113: 321-333
  • [55] Harford WV, Barnett C, Lee E, Perez-Perez G, Blaser MJ, Peterson WL (2000). Acute gastritis with hypochlorhydria: report of 35 cases with long term follow up, Gut, 47: 467-472
  • [56] Amieva MR, El-Omar EM (2008). Host-bacterial interactions in Helicobacter pylori infection, Gastroenterology, 134: 306-323
  • [57] Murata-Kamiya N, Kurashima Y, Teishikata Y, Yamahashi Y, Saito Y, Higashi H, Aburatani H, Akiyama T, Peek RM, Azuma T, Hatakeyama M (2007). Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells, Oncogene, 26: 4617-4626
  • [58] Saadat I, Higashi H, Obuse C, Umeda M, Murata-Kamiya N, Saito Y, Lu H, Ohnishi N, Azuma T, Suzuki A, Ohno S, Hatakeyama M (2007). Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity. Nature, 447: 330-333
  • [59] Ohnishi N, Yuasa H, Tanaka S, Sawa H, Miura M, Matsui A, Higashi H, Musashi M, Iwabuchi K, Suzuki M, Yamada G, Azuma T, Hatakeyama M (2008). Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse, Proc Natl Acad Sci USA, 105: 1003-1008
  • [60] Wang F, Wu X, Liu Z, Bu G, Li X, Qu N, Peng J, Xu C, Shen S, Yuan Y, (2015). Association between Virulence Factors and TRAF1/4-1BB/Bcl-xL Expression in Gastric Mucosa Infected with Helicobacter pylori, Gastroenterol Res Pract, 2015: 648479
  • [61] Wang TR, Peng JC, Qiao YQ, Zhu MM, Zhao D, Shen J, Ran ZH (2014). Helicobacter pylori regulatesTLR4 and TLR9 during gastric carcinogenesis, Int J Clin Exp Pathol, 7: 6950-6955
  • [62] Castaño-Rodríguez N, Kaakoush NO, Mitchell HM (2014). Pattern recognition receptors and gastric cancer, Front Immunol, 5: 336
  • [63] Jeon C, Chang SC, Mu L, Zhao J, Rao JY, Lu QY, Zhang ZF (2013). Genetic variants of peroxisome proliferator-activated receptor δ are associated with gastric cancer. Dig Dis Sci, 58: 2881-2886
  • [64] Deen NS, Huang SJ, Gong L, Kwok T, Devenish RJ (2013). The impact of autophagic processes on the intracellular fate of Helicobacter pylori: more tricks from an enigmatic pathogen? Autophagy, 9: 639-652.
  • [65] Greenfield LK, Jones NL (2013). Modulation of autophagy by Helicobacter pylori and its role in gastric carcinogenesis, Trends Microbiol, 21: 602-612
  • [66] Saberi S, Douraghi M, Azadmanesh K, Shokrgozar MA, Zeraati H, Hosseini ME, Mohagheghi MA, Parsaeian M, Mohammadi M (2012). A potential association between Helicobacter pylori CagA EPIYA and multimerization motifs with cytokeratin 18 cleavage rate during early apoptosis. Helicobacter, 17: 350-357.
  • [67] Jiang X, Wang X (2004). Cytochrome C-mediated apoptosis, Annu Rev Biochem, 73: 87-106
  • [68] Ashktorab H, Dashwood RH, Dashwood MM, Zaidi SI, Hewitt SM, Green WR, Lee EL, Daremipouran M, Nouraie M, Malekzadeh R, Smoot DT (2008). H. pylori-induced apoptosis in human gastric cancer cells mediated via the release of apoptosis-inducing factor from mitochondria. Helicobacter, 13: 506-517
  • [69] Iwai H, Kim M, Yoshikawa Y, Ashida H, Ogawa M, Fujita Y, Muller D, Kirikae T, Jackson PK, Kotani S, Sasakawa C (2007). A bacterial effector targets Mad2L2, an APC inhibitor, to modulate host cell cycling. Cell, 130: 611-623.
  • [70] Fan X, Gunasena H, Cheng Z, Espejo R, Crowe SE, Ernst PB, Reyes VE (2000). Helicobacter pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis. J Immunol, 165: 1918-1924
  • [71] Lin WC, Tsai HF, Liao HJ, Tang CH, Wu YY, Hsu PI, Cheng AL, Hsu PN (2014). Helicobacter pylori sensitize TNF-related apoptosis inducing ligand (TRAIL)-mediated apoptosis in human gastric epithelial cells through regulation of FLIP, Cell Death Dis, 5: e1109.
  • [72] Abadi ATB, Ierardi E, Lee YY (2015). Why do we still have Helicobacter pylori in our stomachs? Malays J Med Sci, 22: 70-75
  • [73] Shiota S, Yamaoka Y (2014). Strategy for the treatment of Helicobacter pylori infection, Curr Pharm Des, 20: 4489-4500
  • [74] O’Connor A, Vaira D, Gisbert JP, O’Morain C (2014). Treatment of Helicobacter pylori infection, Helicobacter, 19(1): 38-45
  • [75] Papastergiou V, Georgopoulos SD, Karatapanis S (2014). Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance. World J Gastroenterol, 20: 9898-9911
  • [76] Ferreira J, Moss SF (2014). Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection, Curr Treat Options Gastroenterol, 12: 373-384
  • [77] Prasertpetmanee S, Mahachai V, Vilaichone RK (2013). Improved efficacy of proton pump inhibitor - amoxicillin – clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy, Helicobacter, 18: 270-273
  • [78] Selvaratnam S, Yeoh J, Hsiang J, Patrick AB (2014). A win for the patient: Direct patient notification improves treatment rates of active Helicobacter pylori infection, Australas Med J, 7: 350-354
  • [79] Abadi ATB (2016). Vaccine against Helicobacter pylori Inevitable approach, World J Gastroenterol, 22(11): 3150-3157
  • [80] Chain FH, Gardner AD (1940). Penicillin as a Chemotherapeutic Agent, Lancet, 236: 226-228
  • [81] Fleming A (2001). On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenza, 1929, Bull World Health Organ, 79: 780-790.
  • [82] Ciccaglione AF, Cellini L, Grossi L, Manzoli L, Marzio L (2015). A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study. Helicobacter, 20: 390-396
  • [83] Delchier JC, Malfertheiner P, Thieroff-Ekerdt R (2014). Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori, Aliment Pharmacol Ther, 40: 171-177
  • [84] van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN (1996). Treatment of Helicobacter pylori infection: a review of the world literature, Helicobacter, 1: 6-19
  • [85] Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC (2014). Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol, 29: 1371-1386
  • [86] Kobayashi Y, Hatta Y, Uchino Y (2014). Successful treatment of secondary Helicobacter pylori eradication for chronic immune thrombocytopenic purpura, Platelets, 25: 645
  • [87] Lamarque D (2014). Treatment of Helicobacter pylori infection, Rev Prat, 64: 207-210.
  • [88] Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ (2012). Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report, Gut, 61: 646-664
  • [89] Smith SM, Haider RB, O’Connor H, McNamara D, O’Morain C (2014). Practical treatment of Helicobacter pylori: a balanced view in changing times, Eur J Gastroenterol Hepatol, 26: 819-825
  • [90] Talebi Bezmin Abadi A (2014). Therapy of Helicobacter pylori: present medley and future prospective. Biomed Res Int, 2014: 124607.
  • [91]Talebi Bezmin Abadi A (2014). Helicobacter pylori: Emergence of a Superbug. Front Med (Lausanne), 1: 34
  • [92] Kim SY, Choi DJ, Chung JW (2015). Antibiotic treatment for Helicobacter pylori: Is the end coming? World J Gastrointest Pharmacol Ther, 6: 183-198
  • [93] O’Connor A, Gisbert JP, McNamara D, O’Morain C (2010). Treatment of Helicobacter pylori infection 2010, Helicobacter, 15 Suppl 1: 46-52
  • [94] González Carro P, Pérez Roldán F, De Pedro Esteban A, Legaz Huidobro ML, Soto Fernández S, Roncero Garcia Escribano O, Esteban López-Jamar JM, Pedraza Martin C, Ruíz Carrillo F (2007). Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. J Gastroenterol Hepatol, 22: 60-63
  • [95] Zuccotti GV, Meneghin F, Raimondi C, Dilillo D, Agostoni C, Riva E, Giovannini M (2008). Probiotics in clinical practice: an overview. J Int Med Res, 36 Suppl 1: 1A-53A.
  • [96] Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A (2002). Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol, 97: 2744-2749.
  • [97] Servin AL (2004). Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens, FEMS Microbiol Rev, 28: 405-440
  • [98] Myllyluoma E, Ahlroos T, Veijola L, Rautelin H, Tynkkynen S, Korpela R (2007). Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota, Int J Antimicrob Agents, 29: 66-72
  • [99] Wolvers D, Antoine JM, Myllyluoma E, Schrezenmeir J, Szajewska H, Rijkers GT (2010). Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics, J Nutr, 140: 698S-712S
  • [100] Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, Song IS (2008). The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication, Helicobacter, 13: 261-268
  • [101] Navarro-Rodriguez T, Silva FM, Barbuti RC, Mattar R, Moraes-Filho JP, de Oliveira MN, Bogsan CS, Chinzon D, Eisig JN (2013). Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol, 13: 56.
  • [102] Zheng X, Lyu L, Mei Z (2013). Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig 2013; 105: 445-453.
  • [103] Fijan S (2014). Microorganisms with claimed probiotic properties: an overview of recent literature, Int J Environ Res Public Health, 11: 4745-4767.
  • [104] Yang JC, Lu CW, Lin CJ (2014). Treatment of Helicobacter pylori infection: current status and future concepts, World J Gastroenterol, 20: 5283-5293.
  • [105] Zullo A, Ridola L, Efrati C, Giorgio F, Nicolini G, Cannaviello C, Alvaro D, Hassan C, Gatta L, Francesco VD (2014). First- and second-line Helicobacter pylori eradication with modified sequential therapy and modified levofloxacin-amoxicillin-based triple therapy. Ann Gastroenterol, 27: 357-361
  • [106] Sutton P (2015). At last, vaccine-induced protection against Helicobacter pylori, Lancet, 386: 1424-1425.
  • [107] Ahmed N (2005). 23 years of the discovery of Helicobacter pylori: is the debate over? Ann Clin Microbiol Antimicrob, 4: 17.
  • [108] Pallen MJ, Clayton CL (1990). Vaccination against Helicobacter pylori urease. Lancet, 336: 186-187.
  • [109] Frank R, Klein JP, Ackermans F, Bazin H (1988). Vaccine, Google Patents.
  • [110] Langenberg W, Rauws EA, Houthoff HJ, Oudbier JH, van Bohemen CG, Tytgat GN, Rietra PJ (1988). Follow-up study of individuals with untreated Campylobacter pylori-associated gastritis and of persons with non-ulcer dyspepsia. J Infect Dis, 157: 1245-1249
  • [111] Marathe SA, Sen M, Dasgupta I, Chakravortty D (2012). Differential modulation of intracellular survival of cytosolic and vacuolar pathogens by curcumin. Antimicrob Agents Chemother, 56: 5555-5567.
  • [112] Jurenka JS (2009). Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev, 14: 141-153.
  • [113] Menon VP, Sudheer AR (2007). Antioxidant and anti-inflammatory properties of curcumin, Adv Exp Med Biol, 595: 105-125.
  • [114] Kidd PM (2009). Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts, Altern Med Rev, 14: 226-246.
  • [115] Irving GR, Karmokar A, Berry DP, Brown K, Steward WP (2011). Curcumin: the potential for efficacy in gastrointestinal diseases, Best Pract Res Clin Gastroenterol, 25: 519-534.
  • [116] Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB (2002). Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis, 23: 143-150
  • [117] Mahady GB, Pendland SL, Yun G, Lu ZZ (2002). Turmeric (Curcuma longa) and curcumin inhibit the growth of Helicobacter pylori, a group 1 carcinogen. Anticancer Res, 22: 4179-4181.
  • [118] Sarkar A, De R and Mukhpopadhyay AK, (2016). Curcumin as a potential therapeutic candidate for Helicobacter pylori associated diseases, World J Gastroenterol, 22(9): 2736-2748.
  • [119] Yi-Chia Lee YC, Chiang TH, Chou CK,Tu YK, Liao WC, Wu MS, David Y. Graham DY (2016). Association between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis, Gastroenterology, 1-11.
  • [120] Cover TL. 2016. Helicobacter pylori diversity and gastric cancer risk. mBio 7(1): e01869-15.
  • [121] Zeng M, Mao XH, Li JX, Tong WD, Wang B, Zhang YJ, Guo G, Zhao ZJ, Li L, Wu DL, Lu DS, Tan ZM, Liang HY, Wu C, Li DH, Luo P, Zeng H, Zhang WJ, Zhang JY, Guo BT, Zhu FC, Zou QM (2015). Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 386: 1457-1464.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-006f9589-6647-47e0-82ef-cbe7dc953c6b
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.